Articles tagged with Leukemia
Researchers developed a biomimetic platform to enhance CAR T cell therapy against leukemia by creating a molecular bridge that reinforces the interface between CAR T cells and leukemia cells. This platform, called FACE, uses ferritin to bind to CD71 on leukemia cells, improving cell recognition and elimination.
Researchers from Dresden University Medicine developed a new treatment approach for relapsed acute myeloid leukemia (AML), combining standard therapy with the BCL2 inhibitor venetoclax. The innovative combination therapy has shown promising efficacy, increasing remission rates to 75% and improving patients' chances of recovery.
A new test detects infection-causing pathogens days before standard blood cultures, offering a potential approach to protecting vulnerable patients. The test, named plasma microbial cell-free DNA sequencing (mcfDNA-Seq), reliably identifies the most common bacteria and fungi that cause bloodstream infections in children with cancer.
The Alliance for Clinical Trials in Oncology will host a webinar highlighting recent clinical advances in breast cancer, multiple myeloma, and leukemia. Researchers will present key findings from ASH and SABCS meetings, impacting treatment outcomes.
A new study has mapped the structure and function of healthy children's bone marrow cells, revealing age-dependent differences in blood cell formation. The atlas provides a valuable resource for researchers to better understand childhood leukemia and other blood disorders.
A multi-institutional effort aims to refine relapse prediction by identifying genetic markers in blood samples from patients with rare blood cancer. Analyzing blood samples from 190 patients, researchers found that tiny traces of persistent NPM1 mutation were linked to worse outcomes and lower survival rates.
Dr. Zon's pioneering research has illuminated how blood develops in embryos, leading to a deeper understanding of rare blood diseases, including pregnancy complications. His discoveries have also led to breakthrough treatments for genetic blood disorders affecting babies and children.
Researchers developed a new method to discover molecular glues through large-scale chemistry and cell-based screening. They identified compounds that selectively degrade ENL in leukemia cells, demonstrating the potential of this approach for targeting previously undruggable proteins.
The American Society of Hematology released guidelines for frontline and relapsed/refractory management of acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), outlining optimal approaches to treating high-risk patient populations. The guidelines highlight the need for additional research on immunotherapies and tr...
A case report investigates a woman's development of acute lymphoblastic leukemia and lymphoblastic lymphoma after receiving her second dose of the Pfizer-BioNTech COVID-19 mRNA vaccine, highlighting potential genetic and molecular mechanisms involved in disease pathogenesis.
Researchers developed an AI tool called ONCO-ACS to predict the risk of secondary heart attacks in cancer patients after a heart attack. The tool combines cancer-related factors with standard clinical data to provide reliable information for doctors to balance treatment benefits and harms.
The ACHILLES project trains researchers in experimental haematological oncology, developing advanced models, analysis tools, and therapeutic targets for leukaemia and lymphoma. The project aims to bridge basic and preclinical research with clinical practice, improving survival rates and accessibility to innovative treatments.
Cancer mortality rates have decreased for breast cancer and leukemia, despite increasing incidence, while colorectal cancer has become the leading cause of death among US young adults. Colorectal cancer surpasses lung, breast, and prostate cancers as the leading cancer-related death in people under 50 years old.
Predictions for lung cancer death rates among EU and UK women indicate stabilization of mortality rates at 12.5 deaths per 100,000 in 2026. Lung cancer remains the leading cause of cancer death for both sexes in the EU, with mortality rates continuing to decline among men.
New studies from Sylvester reveal that 40% of cancers are preventable and that lifestyle interventions can play a crucial role in cancer treatment. Researchers also discovered PFAS on firefighter gear, which may limit exposure to hazardous chemicals linked to cancer.
Researchers at MD Anderson have made significant advancements in cancer treatment, demonstrating the effectiveness of immunotherapy before and after surgery in improving lung cancer patient outcomes. Additionally, a new study shows promise in using CAR T cell therapy to treat large B-cell lymphoma, reducing relapse rates.
A global review of COVID-19 vaccination and infection cases found associations between the two and certain types of cancer. The study analyzed 69 publications and identified potential biological mechanisms, including immune responses and inflammation.
A new qualitative study highlights the profound toll of caregiving on family members of individuals with acute leukemia. Caregivers described living in two worlds, one dominated by cancer and another defined by their personal lives. The findings underscore the need for caregiver support as standard cancer care.
A virtual diet and exercise program has been shown to reduce treatment side effects and increase treatment retention, according to a Sylvester study presented at ASH 2025. Lifestyle interventions can also help patients with blood cancers such as MDS and large B-cell lymphoma receive more effective and less toxic treatments.
Chromatin accessibility maps reveal that MDS stem cells gradually lose their normal identity and acquire characteristics typical of myeloid progenitors. A 'progenitor score' developed by the team tracks cell movement toward a progenitor-like state, correlating with disease severity and prognosis.
Researchers at USC's Keck School of Medicine have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer. The engineered CAR T cells may offer a way to more safely treat blood cancers and reduce the chance of relapse.
A new trial shows pirtobrutinib to be more effective than bendamustine plus rituximab in treating previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The drug demonstrated improved survival rates, a favorable safety profile, and lower adverse event rates compared to the standard treatment.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have identified a small molecule that can inhibit cancer-driving protein IGF2BP3, slowing leukemia growth and triggering cancer cell death. The discovery could lead to new treatments for leukemia and other hard-to-treat cancers.
A new national study reveals a strong link between Agent Orange exposure and the risk of developing myelodysplastic syndrome, with exposed veterans diagnosed at younger ages and experiencing more aggressive disease. The study found that those with MDS were nearly twice as likely to see their disease progress within two years after diag...
A new treatment using genome-edited immune cells has shown promising results in helping children and adults fight a rare form of blood cancer called T-cell acute lymphoblastic leukaemia (T-ALL). The gene therapy, known as BE-CAR7, uses base-editing to modify T-cells and destroy cancerous cells.
A Mount Sinai study found that the timing of a genetic mutation in children with leukemia can significantly impact its aggressiveness. The researchers discovered that leukemia caused by mutations occurring before birth is often more aggressive and harder to treat than those occurring later in life.
Researchers from City of Hope presented results on novel cellular and immunotherapies, treatment strategies for hard-to-treat blood cancers, and a first-in-human trial for GVHD. The studies showed promising outcomes, including higher event-free survival rates and fewer side effects.
Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met its primary endpoint in terms of overall response rate compared to covalent BTK inhibitor ibrutinib. The study suggests pirtobrutinib shows promise as initial BTK inhibitor therapy for patients with CLL and SLL.
A new study found that a chemo-free combination treatment outperformed targeted therapy and chemotherapy in patients with Ph+ acute lymphoblastic leukemia, achieving higher rates of event-free survival and complete remission. Researchers recommend this approach as the new standard of care for this patient group.
A new trial comparing continuous and fixed-duration treatments for CLL found equivalent outcomes in terms of risk of death or disease progression. Fixed-duration treatment was non-inferior to continuous treatment, suggesting clinically equal efficacy.
Patients with B-acute lymphoblastic leukemia who have no evidence of remaining cancer cells experienced comparable outcomes whether they received chemotherapy-based conditioning or total body irradiation. The study's findings could allow more patients to avoid TBI and its associated long-term side effects.
Black patients with acute myeloid leukemia are diagnosed at younger ages and have worse outcomes compared to white patients, according to a study analyzing data from 10 clinical trials over 34 years. The study found that Black patients had a higher risk of dying from AML and any cause, even when treated with similar mutations.
Researchers found that measurable residual disease (MRD) is strongly associated with long-term outcomes in AML patients, providing a reliable indicator of treatment response. MRD testing may help refine how physicians assess treatment efficacy and personalize post-remission care.
Nearly one-third of families with children being treated for acute lymphoblastic leukemia (ALL) experience serious financial difficulties, including losing 25% or more of their household income. The study, led by Dr. Daniel Zheng, found that nearly a third of families struggled to meet basic living costs during their child's treatment.
The updated 2025 American Society of Hematology guidelines recommend that most older adults with acute myeloid leukemia (AML) receive treatment, including gentler chemotherapy regimens and targeted therapies. The guidelines aim to provide more personalized and effective care for this patient population.
Researchers at the University of Virginia Health System have developed a new treatment for acute myeloid leukemia, a deadly form of blood cancer. The FDA-approved medication works by disrupting cellular protein interactions that drive leukemia cell growth and survival, offering patients a potential cure.
Researchers have developed a system called CytoDiffusion that uses generative AI to study the shape and structure of blood cells. The system can accurately identify normal blood cell appearances and spot unusual or rare cells that may indicate disease, outperforming existing systems in tests.
The study reveals that mutated and unmutated CLL subtypes originate from distinct stages of B cell development. New molecular biomarkers, including genes LPL, ZNF667, and ZNF667-AS1, have been identified for more precise patient stratification.
Researchers from the University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center will present their work on various hematological conditions at ASH 2025. These posters highlight recent findings in fields such as von Willebrand disease, multiple myeloma, and acute myeloid leukemia.
City of Hope experts will highlight advances in blood cancer research, cellular therapies, and precision medicine at the 2025 American Society of Hematology Annual Meeting and Exposition. The meeting will feature over 105 sessions covering topics such as CAR T cell therapy, transplant innovations, and precision medicine.
Researchers identified a new subtype of T-cells that do not respond to current treatments and could impact clinical care. A genetic marker, ZBTB16, was found to be switched on in these cells, which can be used to identify them.
Multiple Sylvester physicians presented their research on various hematological cancers, including lymphoma and myeloma. The studies showcased promising results for treatments such as CAR-T therapy and immunotherapy combinations.
A combination treatment of ibrutinib and ianalumab allowed some patients with CLL to discontinue daily therapy and potentially improve their quality of life. The study found that 43.6% of patients had undetectable measurable residual disease, and 17 patients were able to stop ibrutinib and remain off therapy for 12 to 24 months.
Scientists at St. Jude Children's Research Hospital identified a mechanism behind pro-cancer gene expression in a high-risk AML subtype. Inhibiting Exportin-1 showed promise as a novel strategy to treat UBTF-TD AML, which is characterized by treatment resistance and relapse.
Researchers have identified a new histone variant, macroH2A1.1, as a potential therapeutic target for treating Acute Myeloid Leukaemia. The study found that targeting this variant is safe for patients and may lead to new treatment options.
Scientists re-engineered a common chemotherapy drug to make it more soluble and effective, targeting cancer cells while leaving healthy tissues unharmed. The new nanomedicine significantly extended survival in animal models of leukemia, showing promise for improved cancer treatment.
BH3 mimetics demonstrate potent anti-cancer activity by targeting pro-survival BCL-2 proteins, effectively eradicating leukaemia cells with complex mutations. The review highlights several important findings about BH3 mimetics and their role in treating acute myeloid leukaemia.
Researchers found a targeted immunotherapy regimen yielded promising survival outcomes for patients with B-cell ALL, outperforming historical results. The treatment was well-tolerated, with more than half completing the full course of therapy, and responded similarly in patients with complex medical histories.
Researchers found a protein that lets cancer cells reshape their mitochondria to protect themselves from venetoclax, a standard treatment for acute myeloid leukemia. Blocking this protein with experimental compounds restored the drug's effectiveness and prolonged survival in mice.
Recent studies from Sylvester have uncovered links between breast cancer, Superfund sites and social adversity. Researchers are also exploring the use of artificial intelligence (AI) in interpreting mammograms more accurately.
Researchers at MD Anderson have discovered a previously unknown mechanism that explains how bacteria can drive treatment resistance in patients with oral and colorectal cancer. The study also identifies a new biomarker for improved immunotherapy responses in solid tumors.
The Josep Carreras Institute is pioneering Spatial Transcriptomics to understand tumor structure at the cellular level. The institute's guidance on this methodology offers practical solutions for improving reproducibility and clinical application.
Researchers at the University of Cambridge have developed a new lab-grown human embryo model that replicates early human development, including the production of blood stem cells. The 'hematoids' model mimics the natural developmental process, offering potential medical advances in screening drugs and studying blood disorders.
Scientists at Institut Pasteur and Inserm developed a triple-therapy approach to treat blood cancers like lymphomas and leukemias. They induced necroptosis in malignant B cells, which activates the immune system to eliminate tumor cells.
A study of 9/11 first responders found mutations in blood-forming cells may explain increased leukemia risk, suggesting a targeted intervention against environmental toxins. The research also identified IL1RAP as a protein culprit, which could be used to prevent or treat blood cancers in individuals exposed to similar disasters.
A Virginia Tech oncologist is championing a precise approach to treating acute myeloid leukemia by tracking subtle molecular changes in patients. His work aims to identify signs of potential relapse and tailor treatment for each individual with this rare blood cancer.
A groundbreaking study enrolls 465 AYA cancer patients to test if chatbot technology and digital education tools increase uptake of genetic counseling and improve patient outcomes. The trial aims to address longstanding gaps in genetic services for AYAs aged 18-39, who often receive care with limited access to genetic specialists.
Researchers identified two lymphocyte subpopulations associated with arsenic trioxide therapy for APL, the CD8 ISG T cells and NK NFκB cells, which provide new insights into its mechanism of action. ATO treatment also revitalized dysfunctional NK cells and remodelled immunoglobulin proteins.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center identify IGF2BP3 as a master switch linking cancer metabolism and RNA regulation in leukemia cells. The protein shifts energy breakdown and RNA modifications to support cell survival and multiplication.
A team of researchers led by Dr. Manel Esteller has published a study on the longest-lived person ever recorded, Maria Branyas, who reached 117 years. The analysis reveals a fascinating duality: simultaneous presence of signals of extreme aging and healthy longevity. Despite signs of aging, Branyas had genetic characteristics associate...